| Reaction Details |
|---|
 | Report a problem with these data |
| Target | Potassium channel subfamily K member 2 |
|---|
| Ligand | BDBM50254790 |
|---|
| Substrate/Competitor | n/a |
|---|
| Meas. Tech. | TREK1 Assay |
|---|
| pH | 7.3±n/a |
|---|
| Temperature | 295.15±n/a K |
|---|
| EC50 | 9000±n/a nM |
|---|
| Comments | extracted |
|---|
| Citation |  Viswanath, AN; Jung, SY; Hwang, EM; Park, KD; Lim, SM; Min, SJ; Cho, YS; Pae, AN Identification of the first in silico-designed TREK1 antagonists that block channel currents dose dependently. Chem Biol Drug Des88:807-819 (2016) [PubMed] Article |
|---|
| More Info.: | Get all data from this article, Assay Method |
|---|
| |
| Potassium channel subfamily K member 2 |
|---|
| Name: | Potassium channel subfamily K member 2 |
|---|
| Synonyms: | KCNK2 | KCNK2_HUMAN | Outward rectifying potassium channel protein TREK-1 | TREK | TREK-1 K(+) channel subunit | TREK1 | Twik-RElated Potassium (K+) channel 1 (TREK1) | Two pore domain potassium channel TREK-1 | Two pore potassium channel TPKC1 |
|---|
| Type: | Protein |
|---|
| Mol. Mass.: | 47099.16 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | O95069 |
|---|
| Residue: | 426 |
|---|
| Sequence: | MLPSASRERPGYRAGVAAPDLLDPKSAAQNSKPRLSFSTKPTVLASRVESDTTINVMKWK
TVSTIFLVVVLYLIIGATVFKALEQPHEISQRTTIVIQKQTFISQHSCVNSTELDELIQQ
IVAAINAGIIPLGNTSNQISHWDLGSSFFFAGTVITTIGFGNISPRTEGGKIFCIIYALL
GIPLFGFLLAGVGDQLGTIFGKGIAKVEDTFIKWNVSQTKIRIISTIIFILFGCVLFVAL
PAIIFKHIEGWSALDAIYFVVITLTTIGFGDYVAGGSDIEYLDFYKPVVWFWILVGLAYF
AAVLSMIGDWLRVISKKTKEEVGEFRAHAAEWTANVTAEFKETRRRLSVEIYDKFQRATS
IKRKLSAELAGNHNQELTPCRRTLSVNHLTSERDVLPPLLKTESIYLNGLTPHCAGEEIA
VIENIK
|
|
|
|---|
| BDBM50254790 |
|---|
| n/a |
|---|
| Name | BDBM50254790 |
|---|
| Synonyms: | (S)-Norfluoxetine | CHEMBL465123 | NORFLUOXETINE |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C16H16F3NO |
|---|
| Mol. Mass. | 295.2995 |
|---|
| SMILES | NCC[C@H](Oc1ccc(cc1)C(F)(F)F)c1ccccc1 |r| |
|---|
| Structure | 
|
|---|
Search and Browse
